Amarin Corporation plc Sponsored ADR (AMRN)
Summary
Bears are Losing Control Over Amarin (AMRN), Here's Why It's a 'Buy' Now
Amarin (AMRN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Is Amarin (AMRN) Outperforming Other Medical Stocks This Year?
Here is how Amarin (AMRN) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.
All You Need to Know About Amarin (AMRN) Rating Upgrade to Strong Buy
Amarin (AMRN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Amarin Corporation plc Sponsored ADR Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| WH William Herlihy RESOURCES MANAGEMENT Corp. /CT/ /ADV | 60 | $537.6 | $862.8 | $325.2 | 60.49% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 98 | $1,589.56 | $1,422.41 | -$167.15 | -10.52% |
 Point72 Asset Management LP Point72 Asset Management LP | 240,761 | $3.46M | $3.47M | $2,778.43 | 0.08% |
 John Nowicki LCM Capital Management Inc. | 43,462 | $702,841.64 | $625,635.49 | -$77,206.15 | -10.98% |
| SE Sima Elimelech Activest Wealth Management | 50 | $811 | $723 | -$88 | -10.85% |
Amarin Corporation plc Sponsored ADR Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Paul Choi Goldman Sachs | - | - | - | - | - |
Amarin Corporation plc Sponsored ADR (AMRN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Amarin Corporation plc Sponsored ADR ever had a stock split?
Amarin Corporation plc Sponsored ADR Profile
| Biotechnology Industry | Healthcare Sector | Aaron D. Berg CEO | NASDAQ (CM) Exchange | 023111404 CUSIP |
| IE Country | 80 Employees | - Last Dividend | 11 Apr 2025 Last Split | - IPO Date |
Overview
Amarin Corporation plc stands as a noteworthy entity within the pharmaceutical landscape, dedicating its efforts to developing and commercializing therapeutic treatments aimed at combating cardiovascular diseases. With a geographical footprint spanning the United States, various European countries, Canada, Lebanon, and the United Arab Emirates, Amarin has established a significant presence in the global healthcare sector. The company's journey began under the name Ethical Holdings plc but underwent a rebranding to Amarin Corporation plc in 1999, marking a new chapter in its history. Since its inception in 1989, Amarin has been headquartered in Dublin, Ireland, serving as a testament to its enduring commitment to advancing cardiovascular health through innovative pharmaceutical solutions. At the heart of its collaborative endeavors is a strategic partnership with Mochida Pharmaceutical Co., Ltd., focusing on the development and commercialization of drug products and new therapeutic indications derived from the active pharmaceutical ingredient in its flagship product, Vascepa.
Products and Services
- VASCEPA
VASCEPA stands out as Amarin Corporation plc's premier product offering, distinguished by its formulation as a prescription-only omega-3 fatty acid. This distinctive pharmacological product is specifically designed as an adjunct to diet for the purpose of reducing triglyceride levels in adult patients diagnosed with severe hypertriglyceridemia. The commercialization of VASCEPA primarily targets wholesalers and specialty pharmacy providers, thereby ensuring its accessibility to the patient population in need of this critical intervention for managing cardiovascular health. Through this endeavor, Amarin accentuates its commitment to addressing the intricate challenges associated with cardiovascular diseases, leveraging the therapeutic potential of omega-3 fatty acids to enhance patient outcomes.
